Cohance Lifesciences Limited (NSE:COHANCE)

Market Cap	196.33B
Revenue (ttm)	12.11B
Net Income (ttm)	1.77B
Shares Out	382.57M
EPS (ttm)	6.88
PE Ratio	74.60
Forward PE	37.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,497,902
Average Volume	511,142
Open	520.20
Previous Close	518.30
Day's Range	511.25 - 522.80
52-Week Range	511.95 - 1,328.00
Beta	0.45
RSI	26.86
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1989
• Employees: 1,212
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: COHANCE

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.